# S&P US Health Care Sel. Sec. UCITS ETF Accum Ptg USD (GXLV) **Page:** https://fundology.uk/fund/gxlv · ISIN IE00BWBXM617 ## At a glance > Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise. As of 13/11/2026, GXLV (S&P US Health Care Sel. Sec. UCITS ETF Accum Ptg USD, ISIN IE00BWBXM617) closed at £44.38 on the London Stock Exchange. Its ongoing charge is 0.15% a year (about £15 on £10,000). Over the five years to 13/11/2026 its total return was +32.6%, or +3.5% after UK CPIH inflation. ## Summary SSgA SPDR ETFs Europe II Plc - S&P US Health Care Sel. Sec. UCITS ETF Accum Ptg USD is an exchange-traded fund (ETF) from SPDR, launched in 2015. It tracks the S&P Health Care Select Sector Daily Capped 35/20 Index. You buy and sell it through a share-dealing account or platform during stock-market hours, like a share. Its ongoing charge is 0.15% a year — about £15 a year on every £10,000 invested, taken from the fund's value rather than billed to you. Income from its investments is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you. Latest close: **£44.38** (13/11/2026). ## Key facts | Fact | Value | |---|---| | Ticker (LSE) | GXLV | | ISIN | IE00BWBXM617 | | Also listed as | SXLV (London Stock Exchange, US dollars), ZPDH (Xetra, euros) | | Category | Healthcare | | Type | ETF | | Provider | SPDR | | Tracks | S&P Health Care Select Sector Daily Capped 35/20 Index | | Income | Accumulating | | Ongoing charge | 0.15% a year (£15 per £10,000) | | Fund size | £501m | | Launched | 2015 | | Domicile | Ireland | | UK reporting fund status | Yes — on HMRC’s list of reporting funds (list of 02/11/2026); reporting fund since 07/07/2015 | ## Past returns (periods to 13/11/2026) After the fund's ongoing charges. "Income reinvested" is total return; "price only" leaves out income paid out. Real returns are after UK CPIH inflation. | Window | Return | After CPIH inflation | Measured as | |---|---|---|---| | 1 year | +30.49% | +25.87% | price only | | 3 years | +32.48% | +19.69% | income reinvested | | 5 years | +32.64% | +3.54% | income reinvested | Returns: as reported (delayed data) and worked out from recorded daily closes. Inflation: UK CPIH, latest month published. ## Calendar-year returns Calendar-year returns of SSgA SPDR ETFs Europe II Plc - S&P US Health Care Sel. Sec. UCITS ETF Accum Ptg USD in pounds (price, with income reinvested in the fund): 2023 −3.9%, 2024 +5.7%, 2025 +4.4%; 2026 to 13/11/2026 +25.0%. Returns of SSgA SPDR ETFs Europe II Plc - S&P US Health Care Sel. Sec. UCITS ETF Accum Ptg USD in pounds (price, with income reinvested in the fund) over the 12 months to 30/09/2026: +20.8%; to 30/09/2025: −5.1%; to 30/09/2024: +9.7%; to 30/09/2023: −2.9%. | Year | Return | After CPIH inflation | Measured as | |---|---|---|---| | 2023 | -3.9% | -7.7% | Price | | 2024 | +5.7% | +2.1% | Price | | 2025 | +4.4% | +0.8% | Price | | 2026 to 13/11/2026 | +25.0% | +21.0% | Price | ## Risk metrics | Window | Volatility | Max drawdown | |---|---|---| | 1 year | 17.08% | -10.67% | | 3 years | 14.58% | -19.00% | ## Largest fall Volatility of SSgA SPDR ETFs Europe II Plc - S&P US Health Care Sel. Sec. UCITS ETF Accum Ptg USD in pounds, annualised from weekly returns to 13/11/2026: 17.1% over 1 year, 14.6% over 3 years. Largest fall in the price of SSgA SPDR ETFs Europe II Plc - S&P US Health Care Sel. Sec. UCITS ETF Accum Ptg USD since April 2022, in pounds: −19.0% from 31/01/2025 to 23/05/2025. The lowest 12-month return of SSgA SPDR ETFs Europe II Plc - S&P US Health Care Sel. Sec. UCITS ETF Accum Ptg USD in pounds (price, with income reinvested in the fund) since April 2022 was −16.7% (12 months to 08/08/2025); the highest was +29.2% (12 months to 25/09/2026). On 13/11/2026 the price of SSgA SPDR ETFs Europe II Plc - S&P US Health Care Sel. Sec. UCITS ETF Accum Ptg USD was at its highest weekly close since April 2022, in pounds. ## Charges compared with similar funds Ongoing charge of SSgA SPDR ETFs Europe II Plc - S&P US Health Care Sel. Sec. UCITS ETF Accum Ptg USD 0.15% a year. Compared on 14/11/2026, 25 of the 28 other healthcare funds charge more, 1 the same and 2 less (share classes counted once). ## Charges & eligibility - Ongoing charges figure (OCF): **0.15%** per year (as of 13/11/2026) - Stocks and shares ISA eligible: usually (check with your platform) - SIPP eligible: usually (check with your provider) - ISA and SIPP mean the kind of product usually qualifies under HMRC rules. We do not check each platform’s list — each provider decides which funds it offers. Crypto ETNs have not qualified for a stocks and shares ISA since 06/04/2026, and overseas funds that are not UK-recognised UCITS, such as Swiss ETFs, do not usually qualify. ## What it holds As of 05/11/2026, GXLV holds 61 positions, according to its published holdings. The largest is Eli Lilly at 16.32% of the fund; the ten largest make up 60.5%. ### Top holdings Largest positions (as of 05/11/2026), as a percentage of the whole fund: | # | Holding | Ticker | Weight | |---|---|---|---| | 1 | Eli Lilly | [LLY](https://fundology.uk/stock/LLY) | 16.32% | | 2 | Johnson & Johnson | [JNJ](https://fundology.uk/stock/JNJ) | 9.81% | | 3 | AbbVie | [ABBV](https://fundology.uk/stock/ABBV) | 7.61% | | 4 | Merck | [MRK](https://fundology.uk/stock/MRK) | 5.42% | | 5 | UnitedHealth Group | [UNH](https://fundology.uk/stock/UNH) | 5.31% | | 6 | Thermo Fisher Scientific | [TMO](https://fundology.uk/stock/TMO) | 3.74% | | 7 | Amgen | [AMGN](https://fundology.uk/stock/AMGN) | 3.72% | | 8 | Gilead Sciences | [GILD](https://fundology.uk/stock/GILD) | 3.10% | | 9 | Abbott Laboratories | [ABT](https://fundology.uk/stock/ABT) | 2.94% | | 10 | Pfizer | [PFE](https://fundology.uk/stock/PFE) | 2.54% | The 60 holdings on record (of 61 reported): https://fundology.uk/fund/gxlv/holdings ## Questions people ask **What is the ongoing charge of GXLV?** The ongoing charge of GXLV is 0.15% a year — about £15 a year on every £10,000 invested, taken from the fund’s value rather than billed to you. Platform and dealing fees are charged separately. Ongoing charge of SSgA SPDR ETFs Europe II Plc - S&P US Health Care Sel. Sec. UCITS ETF Accum Ptg USD 0.15% a year. Compared on 14/11/2026, 25 of the 28 other healthcare funds charge more, 1 the same and 2 less (share classes counted once). **What does GXLV track?** GXLV tracks the S&P Health Care Select Sector Daily Capped 35/20 Index. **Is GXLV accumulating or distributing?** GXLV is accumulating: income is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you. **What is the ISIN of GXLV?** The ISIN of GXLV is IE00BWBXM617. An ISIN identifies one exact share class of a fund; GXLV is its ticker on the London Stock Exchange. The same share class is also listed as SXLV (London Stock Exchange, US dollars) and ZPDH (Xetra, euros). **What does GXLV hold?** As of 05/11/2026, GXLV holds 61 positions, according to its published holdings. The largest is Eli Lilly at 16.32% of the fund; the ten largest make up 60.5%. Its ten largest holdings are Eli Lilly (16.32%), Johnson & Johnson (9.81%), AbbVie (7.61%), Merck (5.42%), UnitedHealth Group (5.31%), Thermo Fisher Scientific (3.74%), Amgen (3.72%), Gilead Sciences (3.10%), Abbott Laboratories (2.94%) and Pfizer (2.54%). **What were GXLV’s returns in each of the last five years?** Calendar-year returns of GXLV in pounds (price, with income reinvested in the fund): 2023 −3.9%, 2024 +5.7%, 2025 +4.4%; 2026 to 13/11/2026 +25.0%. Past performance is not a guide to future returns. **How has GXLV done after inflation?** Over the five years to 13/11/2026 GXLV’s total return was +32.6%, or +3.5% after UK CPIH inflation. Past performance is not a guide to future returns. ## Fund documents - [Fund page at State Street Global Advisors](https://www.ssga.com/uk/en_gb/intermediary/etfs/state-street-spdr-sp-us-health-care-select-sector-ucits-etf-acc-zpdh-gy) - [Key investor information document (KIID)](https://www.ssga.com/library-content/kiids?isin=IE00BWBXM617&documentType=kiid&country=uk&language=en_gb&ticker=zpdh-gy) - [Factsheet](https://www.ssga.com/library-content/products/factsheets/etfs/emea/factsheet-emea-en_gb-zpdh-gy.pdf) - Links checked 12/10/2026. --- We show information. We are not financial advisers, not authorised by the FCA, and never recommend specific investments. Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.